Citadel Advisors’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-20,463
| Closed | -$82K | – | 10576 |
|
|
2019
Q4 | $82K | Sell |
20,463
-76,293
| -79% | -$358K | ﹤0.01% | 8626 |
|
|
2019
Q3 | $474K | Buy |
+96,756
| New | +$541K | ﹤0.01% | 6850 |
|
|
2019
Q2 | – | Sell |
-709,790
| Closed | -$3.77M | – | 10230 |
|
|
2019
Q1 | $4.12M | Buy |
709,790
+559,866
| +373% | +$5.78M | ﹤0.01% | 3267 |
|
|
2018
Q4 | $2.02M | Buy |
149,924
+126,228
| +533% | +$2.13M | ﹤0.01% | 4143 |
|
|
2018
Q3 | $459K | Sell |
23,696
-104,944
| -82% | -$2.23M | ﹤0.01% | 6840 |
|
|
2018
Q2 | $3.29M | Buy |
128,640
+55,253
| +75% | +$1.29M | ﹤0.01% | 3341 |
|
|
2018
Q1 | $1.48M | Buy |
73,387
+62,854
| +597% | +$1.47M | ﹤0.01% | 4196 |
|
|
2017
Q4 | $211K | Sell |
10,533
-7,880
| -43% | -$155K | ﹤0.01% | 7032 |
|
|
2017
Q3 | $381K | Sell |
18,413
-998,387
| -98% | -$16.9M | ﹤0.01% | 5706 |
|
|
2017
Q2 | $15M | Sell |
1,016,800
-708,529
| -41% | -$11.8M | 0.01% | 1175 |
|
|
2017
Q1 | $27.5M | Buy |
1,725,329
+1,179,253
| +216% | +$17M | 0.03% | 763 |
|
|
2016
Q4 | $6.88M | Buy |
546,076
+437,471
| +403% | +$8.15M | 0.01% | 1673 |
|
|
2016
Q3 | $3.04M | Buy |
+108,605
| New | +$3.64M | ﹤0.01% | 2487 |
|
|
2015
Q4 | – | Sell |
-5,417
| Closed | -$169K | – | 9432 |
|
|
2015
Q3 | $156K | Sell |
5,417
-8,316
| -61% | -$356K | ﹤0.01% | 6467 |
|
|
2015
Q2 | $615K | Buy |
13,733
+12,698
| +1,227% | +$478K | ﹤0.01% | 4658 |
|
|
2015
Q1 | $36K | Buy |
+1,035
| New | +$28.2K | ﹤0.01% | 7599 |
|
Other funds holding DPLO
Citadel Advisors's DPLO Position: Q1 2020 in Review
Citadel Advisors sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2020, closing a stake of 20,463 shares — an estimated $82K sold.
Citadel Advisors first reported a position in DPLO in Q1 2015 and held it in 16 quarters. The position peaked at $27.5M in Q1 2017. 1 fund tracked by Wall St. Rank holds DPLO as of Q1 2020.
- Citadel Advisors reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2020 after selling out during the quarter.
- Citadel Advisors sold 20,463 DIPLOMAT PHARMACY, INC. shares in Q1 2020, an estimated $82K.
- Citadel Advisors first reported a position in DIPLOMAT PHARMACY, INC. in Q1 2015 and held it in 16 quarters.
- Citadel Advisors's DIPLOMAT PHARMACY, INC. position peaked at $27.5M in Q1 2017.
- 1 fund tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2020.
Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.